Accustem Sciences ACUT

AccuStem Sciences, Inc. is a clinical stage diagnostics company focused on developing and commercializing genomic tests for cancer care. Its main activities involve creating and bringing to market proprietary assays that help physicians make treatment decisions for patients with lung nodules and early stage breast cancer. The company operates in the oncology diagnostics sector.

AccuStem Sciences, Inc. expects to generate revenue primarily from the sale of its MSC test for lung nodules and its StemPrintER test for early stage breast cancer. In addition, the company plans to offer ancillary testing services such as hereditary genetic analysis and somatic mutation profiling to complement its core assays. Revenue will be obtained through reimbursement from private insurers, Medicare, Medicaid and direct payments from healthcare providers.

AccuStem Sciences, Inc. positions itself as an early entrant in the genomic diagnostics market for lung nodules and breast cancer. It faces competition from established tests such as Nodify Lung and Percepta for lung nodule assessment and from OncotypeDX, MammaPrint, EndoPredict and Prosigna for breast cancer recurrence risk. The company’s advantages include its proprietary microRNA based MSC assay and its stem cell biology focused StemPrintER platform, which have been validated in large clinical cohorts and shown to improve diagnostic accuracy compared with existing standards.

The company’s customers include hospitals, outpatient clinics, physician laboratories and pathology groups that serve patients undergoing lung cancer screening or breast cancer treatment. Specific customer names are not disclosed in the filing, but the target audience comprises pulmonologists, oncologists, surgeons and other healthcare professionals who order genomic tests to guide patient management.